

## **DEPARTMENT OF HEALTH & HUMAN SERVICES**

## PUBLIC HEALTH SERVICE NATIONAL INSTITUTES OF HEALTH

FOR US POSTAL SERVICE DELIVERY:
Office of Laboratory Animal Welfare
Rockledge One, Suite 360
6705 Rockledge Drive – MSC 7982
Bethesda, Maryland 20892-7982
Home Page: http://grants.nih.gov/grants/olaw/olaw.htm

FOR EXPRESS MAIL:
Office of Laboratory Animal Welfare
Rockledge One, Suite 360
6705 Rockledge Drive
Bethesda, Maryland 20817
<u>Telephone</u>: (301) 496-7163
<u>Facsimile</u>: (301) 402-7065

August 15, 2017

Re: Animal Welfare Assurance A3693-01 [OLAW Case F]

Dr. Keith LeJeune Senior Vice President for Research And Innovation Allegheny-Singer Research Institute 320 East North Avenue Pittsburgh, PA 15212-4772

Dear Dr. LeJeune,

The Office of Laboratory Animal Welfare (OLAW) acknowledges receipt of your June 28, 2017 letter reporting a noncompliance with the PHS Policy on the Humane Care and Use of Laboratory Animals at the Allegheny Singer Research Institute. According to the information provided, it is understood that another AVMA-approved euthanasia method was used in place of the one in the IACUC-approved protocol "Neutrophil Modulation to Treat Type 1 Diabetes Mellitus" (1009). There were no animal welfare concerns. The activity was not PHS-supported.

Corrective actions included amending the protocol to add the euthanasia method. The PI and Research staff were also retrained in the areas of non-compliance. The staff will verify compliance with the protocol before conducting animal procedures.

OLAW believes that the corrective measures by the Allegheny Singer Research Institute are consistent with the provisions of the PHS Policy on Humane Care and Use of Laboratory Animals for institutional self-monitoring, self-correction, and self-reporting. Although this activity was not PHS funded, the application of the standards of the PHS Policy across the animal care and use program reduces any potential appearance of a double standard. We appreciate being informed of this matter and find no cause for further action by this office.

Sincerely,

Brent C. Morse, DVM

Acting Director

Division of Compliance Oversight Office of Laboratory Animal Welfare

cc: IACUC Contact



July 28, 2017

Allegheny-Singer Research Institute 320 East North Avenue Pittsburgh, PA 15212-4772

Axel V. Wolff, M.S., D.V.M.
Director, Division of Compliance Oversight
Office of Laboratory Animal Welfare, National Institutes of Health
6705 Rockledge Drive, Rockledge 1, Suite 360 MSC 7982
Bethesda, MD 20892-7982

RE: Funding Source: ancial informati

Name of Institute: Allegheny Singer Research Institute

Assurance #: D16-00408 (A3693-01)

PI: Nick Giannoukakis, Ph.D.

IACUC Application: "Neutrophil Modulation to Treat Type 1 Diabetes Mellitus" (1009)

Dear Dr. Wolff,

This is letter to report non-compliance that occurred at Allegheny Singer Research Institute (Assurance #: A3693-01). The noncompliance consisted of a failure to adhere to the approved protocol which is a serious deviation as required by The Guide.

Upon internal quality assurance monitoring, it was found that the euthanasia method being conducted was not approved by the IACCU and another AVMA approved method of euthanasia was being. The IACUC has since approved the method of euthanasia through an amendment to the protocol and no animal welfare issues were present since the method was approved by the AVMA.

The Committee discussed this issue at the convened meeting on July 20, 2017. It was determined that no animals were harmed, an AVMA method of euthanasia was used, and the protocol was amended upon discovery of the discrepancy.

The IACUC discussed the incident and accepted the following corrective action plan (CAP) that was implemented:

The PI and Research Staff received mandatory re-training in the areas of non-compliance

Utilizing a verification step that prior to any planned procedures are conducted, the staff will ensure they are
what is in the current protocol and that all individuals involved with animal research are aware of the approved
procedures

If you have any questions, please do not hesitate to contact me.

Sincerely

Keith Leseyne, PhD

SVP Research & Innovation

Institutional Official

C:

Nick Giannoukakis, Ph.D., Pl

Kevin Kelly, MD, PhD, IACUC Chairman

Roger Sembrat, VMD, IACUC Attending Veterinarian

econdary individu System Compliance

AAALAC

File

pager: telephone # page ID 316.
Secondary individual wahn.org

Confidentiality Notice: This e-mail message and any attachments are intended solely for the individual or individuals designated above. It may contain confidential or proprietary information and may be subject to confidentiality protections and may be legally privileged. If you are not the intended recipient, you are not authorized to read, copy, retain or distribute this message. If you receive this message in error, please immediately notify the sender by reply e-mail and delete this message. The sender does not waive any privilege or right of privacy or confidentiality that may attach to this communication. You are not authorized to read, copy, retain, or distribute this message, or disclose its contents to any other person. Thank you.

## Morse, Brent (NIH/OD) [E]

From:

OLAW Division of Compliance Oversight (NIH/OD)

Sent:

Monday, August 14, 2017 11:05 AM

To:

Secondary individual PLAW Division of Compliance Oversight (NIH/OD)

Cc:

Keith Lejeune; ondary individ

Subject:

RE: Notification of noncompliance-Allegheny Singer Research Institute: D16-00408

(A3693-01)

Thank you for sending these two reports. We will send official responses soon.

Regards, Brent Morse

Brent C. Morse, DVM, DACLAM Acting Director Division of Compliance Oversight Office of Laboratory Animal Welfare National Institutes of Health

Please note that this message and any of its attachments are intended for the named recipient(s) only and may contain confidential, protected or privileged information that should not be distributed to unauthorized individuals. If you have received this message in error, please contact the sender.

From: Secondary individual [mailto Secondary individual @ahn.org]

Sent: Monday, August 14, 2017 10:07 AM

**To:** OLAW Division of Compliance Oversight (NIH/OD) <olawdco@od.nih.gov> **Cc:** Keith Lejeune <Keith.Lejeune@ahn.org>; Secondary individual @ahn.org>

Subject: Notification of noncompliance-Allegheny Singer Research Institute: D16-00408 (A3693-01)

Name of Institute: Allegheny Singer Research Institute

Assurance #: D16-00408 (A3693-01)

To Whom It May Concern:

Attached please find reports of noncompliance regarding the determination of serious noncompliance by the IACUC for two internally funded animal protocols (#1009-PI: Nick Giannoukakis and #998-PI: Rita Bottino) for Allegheny Singer Research Institute (D16-00408 (A3593-01)).

If you have any questions, please let me know. Regards,

ondary indivi

Secondary individual

Director, Clinical Research and Regulatory Affairs AHN Research Institute Allegheny Health Network

cell:

phone telephone #
fax telephone #

telephone #